Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis

Rev Neurol (Paris). 2014 Mar;170(3):228-9. doi: 10.1016/j.neurol.2013.11.004. Epub 2014 Mar 18.

Authors

A Bougea¹, E Anagnostou², E Stamboulis², E Kararizou²

Affiliations

¹ Department of Neurology, Athens National University, Aiginition Hospital, Vass. Sofias Ave. 72-74, 11528 Athens, Greece. Electronic address: annita139@yahoo.gr.
² Department of Neurology, Athens National University, Aiginition Hospital, Vass. Sofias Ave. 72-74, 11528 Athens, Greece.

PMID: 24656415
DOI: 10.1016/j.neurol.2013.11.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab
Amyotrophic Lateral Sclerosis / diagnosis
Amyotrophic Lateral Sclerosis / etiology*
Amyotrophic Lateral Sclerosis / immunology
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antirheumatic Agents / adverse effects*
Antirheumatic Agents / therapeutic use
Arthritis, Psoriatic / complications*
Arthritis, Psoriatic / drug therapy
Diagnosis, Differential
Humans
Male
Middle Aged
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / physiology

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Adalimumab